Biogen Stock: Is Wall Street Bullish or Bearish?

Core Insights - Biogen Inc. has a market capitalization of $24.6 billion and specializes in therapies for neurological and neurodegenerative diseases, with a portfolio that includes multiple sclerosis treatments and biosimilars [1] Stock Performance - Over the past 52 weeks, Biogen's stock has risen by 1.6%, underperforming the S&P 500 Index, which gained 13.2% during the same period [2] - Year-to-date, Biogen shares have returned 9.6%, compared to a 14.5% increase in the S&P 500 Index [2] - Biogen has also lagged behind the Health Care Select Sector SPDR Fund, which gained 5.1% over the past 52 weeks [3] Financial Performance - On October 30, Biogen's shares rose by 1.2% after the company reported Q3 2025 adjusted earnings of $4.81 per share, exceeding Wall Street estimates [4] - The company reported stronger-than-expected sales of multiple sclerosis drugs at $1.06 billion, an 80% increase in global Leqembi sales to approximately $121 million, and an 8% growth in its rare-disease portfolio to $533 million [4] Earnings Forecast - For the fiscal year ending December 2025, analysts expect Biogen's adjusted EPS to decline by 9.5% year-over-year to $14.90 [5] - Biogen has a mixed earnings surprise history, having topped consensus estimates in three of the last four quarters [5] Analyst Ratings - Among 33 analysts covering Biogen, the consensus rating is a "Moderate Buy," consisting of 14 "Strong Buy" ratings, one "Moderate Buy," and 18 "Holds" [5] - The current configuration of ratings is more bullish than three months ago, with 12 "Strong Buy" ratings [6] Price Target - On October 31, Baird reduced its price target for Biogen to $250 while maintaining an "Outperform" rating [7] - The mean price target of $176.07 indicates a 5.1% premium to Biogen's current price, while the highest price target of $260 suggests a potential upside of 55.2% [7]